GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Flerie AB (OSTO:FLERIE) » Definitions » LT-Debt-to-Total-Asset

Flerie AB (OSTO:FLERIE) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Flerie AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Flerie AB's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Flerie AB's long-term debt to total assets ratio declined from Sep. 2023 (0.01) to Sep. 2024 (0.00). It may suggest that Flerie AB is progressively becoming less dependent on debt to grow their business.


Flerie AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Flerie AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flerie AB LT-Debt-to-Total-Asset Chart

Flerie AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 - 0.01 0.01

Flerie AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 - -

Flerie AB LT-Debt-to-Total-Asset Calculation

Flerie AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=1.598/299.389
=0.01

Flerie AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.5/4288.5
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Flerie AB  (OSTO:FLERIE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Flerie AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Flerie AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Flerie AB Business Description

Traded in Other Exchanges
Address
Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations.

Flerie AB Headlines

No Headlines